The seventh Alopecia Areata Research Summit, *Forging the Future*, provided a forum for expert researchers and clinicians from a variety of fields to present cutting-edge research, disseminate results from ongoing projects, and foster collaboration around the best ways to further advance alopecia areata research. The 113 Summit participants who gathered December 4 and 5, 2018, in New York City included 33 expert researchers within and outside the field of alopecia areata, 26 early career investigators, 34 biopharmaceutical industry representatives, 10 patient advocates, and 10 representatives from government and other organizations, including the National Institutes of Health (NIH) and the International Dermatology Outcome Measures (IDEOM). All together, more than 35 academic institutions and research centers from the United States and eight countries across the globe were represented.

Our three outstanding co-chairs, Drs. Jerry Shapiro, Natasha Mesinkovska and Angela Christiano, organized two intensive days of scientific programming focused on: (1) the current state of alopecia areata research; (2) clinical research and outcome assessments; (3) patient engagement in clinical development; (4) new frontiers in basic science; and (5) epidemiology, health economics and the burden of this disease.

This report provides highlights of the research presented in each topic area and the future research priorities identified during targeted discussion sessions.

**Meeting Summary**

**CURRENT STATE OF ALOPECIA AREATA RESEARCH**

**Presentation Highlights**

Dr. Natasha Mesinkovska, Chief Scientific Officer of the National Alopecia Areata Foundation and Director of Clinical Research at the University of California Irvine School of Medicine (Irvine, CA), summarized preceding research summits that laid the groundwork for the genetic and immunologic studies, research infrastructure, funding streams and strategic partnerships resulting in the current investigative trajectory.

Dr. Angela Christiano, from Columbia University Medical Center (New York, NY), presented an update on genetics and immunology studies that are central to understanding the underlying mechanisms of alopecia areata. Three new areas of

*Continued on page 2*
Research Summit Summary continued from page 1

research suggest: (a) JAK2 inhibition is not required for efficacy in alopecia areata; (b) JAK 1/3 inhibitors may induce T-cell exhaustion as part of their mechanism of action; and (c) the onset of alopecia areata may be associated with bidirectional dysbiosis in gut microbiota.

Dr. Maria Hordinsky, from the University of Minnesota Medical School (Minneapolis, MN), provided an overview of current treatment practices for adult and pediatric patients with alopecia areata in the absence of FDA-approved therapies. Factors to consider when choosing a treatment include age, location of hair loss, disease extent and activity, associated medical problems—and patient/parent choice after a review of proposed treatment risks, benefits, and expectations. Current treatment of alopecia areata should include a conversation about current clinical research opportunities as well as the off-label use of oral or topical JAK inhibitors.

Dr. Ralf Paus, from the University of Miami (Miami, FL) and the University of Manchester (Manchester, UK), explored the hypothetical scenario that alopecia areata may not be a single disease, but a stereotypic response pattern that every healthy anagen hair follicle will show when interferon gamma immunological damage triggers the pathobiology triad of immune collapse, hair follicle dystrophy, and premature catagen induction. He believes that a personalized medicine approach is needed to treat antigen-specific autoimmune alopecia areata as well as non-antigen-specific forms of the disease.

Dr. Amos Gilhar, from the Technion-Israel Institute of Technology (Haifa, Israel), reviewed the similarities and differences between the C3H/HeJ and humanized mouse models. The histological features of the C3H/HeJ model are not always typical of human alopecia areata so the humanized mouse model should also be used in preclinical testing of new candidate agents for alopecia areata.

CLINICAL RESEARCH AND OUTCOME ASSESSMENTS

Presentation Highlights

Clinical Research

Dr. Brittany Craiglow, a pediatric dermatologist from the Yale School of Medicine and Dermatology Physicians of Connecticut (Fairfield, CT), reviewed several case reports and series on the use of topical and systemic JAK inhibitors for the treatment of alopecia areata in children ages 4 to 17, showing efficacy in at least 50 percent of patients. Multiple ongoing clinical trials evaluating JAK inhibitors for alopecia areata are now enrolling patients ages 12 to 17. While more data is needed to further explore the safety and efficacy of JAK inhibitors in the pediatric population, their use may be considered for children with alopecia areata who are experiencing significant psychosocial impairment; such use should be preceded by a thorough discussion of the risks, benefits and unknowns.

Dr. Brett King, from the Yale School of Medicine (New Haven, CT), evaluated the response of eyebrows and eyelashes in patients with alopecia areata treated with the JAK inhibitor tofacitinib (Xeljanz, from Pfizer) from 2014 to 2018. Of 98 patients with total scalp hair loss, 86 had involvement of both eyebrows and eyelashes. Complete regrowth of all sites (scalp, eyebrows and eyelashes) was achieved in 19 out of 119 patients (16%), highlighting differences in hair follicle biology across different hair-bearing sites.

Dr. Melissa Piliang, from the Cleveland Clinic Lerner College of Medicine (Cleveland, OH), shared results from a retrospective study of 20 patients with alopecia universalis and alopecia totalis treated with 10 to 25 mg tofacitinib (Xeljanz, from Pfizer) over an average of 13 months. Eleven patients (55%) experienced more than 50 percent hair regrowth, seven patients (35%) developed lab abnormalities and six clinical adverse events were reported. Results indicate that tofacitinib is a viable long-term treatment option for severe alopecia areata but further research is needed to understand the variation in efficacy among patients.

Dr. Hind Almohanna, from the University of Miami Miller School of Medicine (Miami, FL), reviewed available data on the efficacy, safety and mechanism of action of platelet-rich plasma (PRP) injections in treating alopecia areata. Although
PRP is relatively safe and potentially effective, there are no standardized protocols or recommendations for the number of PRP sessions required to treat and maintain hair regrowth. Additional large-scale studies are needed to evaluate efficacy as a monotherapy or in association with other therapeutic modalities for alopecia areata.

Jessica Lin, from the University of California Irvine School of Medicine (Irvine, CA), presented a pilot study on the use of multiphoton microscopy (MPM) as an adjunct to histological studies and a diagnostic tool for alopecia areata. Results showed MPM was able to visualize histological features of alopecia areata and may be useful in noninvasive monitoring of disease progression in clinical practice.

Dr. Emma Guttman-Yassky, from the Icahn School of Medicine at Mount Sinai (New York, NY), presented data showing alopecia areata is a highly inflammatory skin disease with increased T helper type 1, T helper type 2, and IL-23 cytokine circuits. Treatment with drugs aimed at specific cytokine inhibition may help uncover the pathogenic contribution of these pathways in alopecia areata.

Dr. Mark Lebwohl, from the Icahn School of Medicine at Mount Sinai (New York, NY), showed how research related to psoriasis and atopic dermatitis models have been helpful in dissecting key immune pathways that play roles in the development of inflammatory skin disease. Following the same methodology and applying narrow-targeted therapeutics may help elucidate the role of each cytokine pathway in the development of alopecia areata.

Dr. Maryanne Senna, from Massachusetts General Hospital (Boston, MA), presented three thought-provoking clinical case reports on the art of treating patients with alopecia areata, and she highlighted the importance of using a personalized approach.

Dr. Chloe Ekelem, from the University of California Irvine School of Medicine (Irvine, CA), shared a series of case studies of three alopecia areata patients treated with platelet-rich plasma (PRP) over the course of three months using noninvasive optical coherence tomography (OCT) imaging to monitor response. The patient who also treated the scalp with a daily application of ice demonstrated the most significant regrowth. Results show that PRP may be effective in the treatment of patchy alopecia areata patients with active lesions, OCT may be useful for monitoring disease progression in clinical practice, and cooling measures may have utility as an adjunct to therapeutic mainstays.

Dr. Elena Peeva, from Pfizer (Cambridge, MA), reported results from an ongoing phase 2a, randomized, double-blind, multicenter study of an oral JAK3 inhibitor (PF-06651600) and an oral TYK2/JAK1 inhibitor (PF-06700841) in patients with moderate to severe alopecia areata. At 24 weeks, both JAK inhibitors demonstrated an improvement in hair regrowth on the scalp relative to baseline as measured by the Severity of Alopecia Tool (SALT) score (PF-06651600: 33.6%; PF-06700841: 49.5%). These results indicate that treatment with PF-06651600 or PF-06700841 was efficacious and well-tolerated in patients with alopecia areata.

Dr. James Cassella, from Concert Pharmaceuticals (Lexington, MA), reported interim results from an ongoing phase 2a, double-blind, randomized, placebo-controlled trial of an oral JAK1/JAK2 inhibitor (CTP-543) in patients with moderate to severe alopecia areata. At 24 weeks, treatment with 8 mg of CTP-543 significantly improved hair regrowth (≥ 50%) in 47 percent of patients with alopecia areata with an acceptable safety profile.

Dr. Ricardo Cibotti, Program Director of Immunobiology and Immune Diseases of Skin at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), shared how alopecia areata is a rapidly expanding area of NIAMS research. The various funding opportunities to support clinical research were reviewed, including an R01 grant (the NIH’s oldest grant mechanism) specifically focused on the pursuit of clinical observational studies to obtain data necessary for designing clinical trials such as disease symptoms, disease progression, comorbid conditions, and outcomes, and an R34 grant (a type of grant often providing early support for research projects) to facilitate the necessary planning, design, and preparation of documentation prior to implementation of investigator-initiated clinical trials.

Continued on page 4
Research Summit Summary continued from page 1

Future Research Priorities

- Develop consensus-driven, evidence-based guidelines for treatment, including statements on the definition of disease, severity subsets, diagnostic criteria, natural history and paths for short/long term management for publication in a peer-reviewed journal.

- Study the differences in hair follicle biology and treatment effects across different hair-bearing sites, including eyebrows and eyelashes.

- Investigate response to therapy among different disease subgroups including new onset patients, patients with longstanding disease and pediatric populations.

Clinical Outcome Assessments

Dr. Elise Olsen, from Duke University Medical Center (Durham, NC), discussed the inherent challenges posed for clinical trials in alopecia areata including the lack of standardized assessment methods and the necessity of taking into account the effect of extent, pattern, and duration of hair loss on regrowth. Dr. Olsen provided an overview of assessment methods including the Severity of Alopecia Tool (SALT), Lesional Density Score (LAD) and Alopecia Density and Extent (ALODEX) scoring systems as well as a potential global score.

Dr. Justin Ko, from Stanford University School of Medicine (Stanford, CA), presented the results of a study to understand the importance of eyebrows in the treatment goals of alopecia areata patients. An online survey of 1,741 patients asked them to assess their satisfaction with various levels of response to treatment, as shown by edited photos depicting a range of eyebrows and scalp hair growth. Results showed that satisfaction with scalp and eyebrow regrowth is nonlinear. More participants were satisfied with complete eyebrows and no scalp hair (69%) than complete eyebrows and partial scalp hair (51%). Future studies may consider looking at eyebrow regrowth as a primary outcome in conjunction with scalp hair regrowth, or potentially as a primary outcome alone.

Dory Kranz, Chief Executive Officer of the National Alopecia Areata Foundation, reported the progress of NAAF’s Patient-Reported Outcome (PRO) Consortium to develop a single, consensus-defined PRO instrument that can be shared across industry partners and other ongoing initiatives to incorporate the voices of patients in alopecia areata research.

Dr. Alice Gottlieb, from the International Dermatology Outcomes Measures (IDEOM) and New York Medical College (New York, NY), presented the ongoing work of IDEOM, including the core domains for psoriasis and hidradenitis suppurativa and the development of global health care provider- and patient-reported outcome measures for clinical practice across multiple dermatologic disorders. Potential areas of mutual interest with IDEOM and NAAF include fundraising, the development of outcome measures, and collaborations with researchers, industry and government.

Dr. Kathleen Wyrwich, from Eli Lilly & Company (Indianapolis, IN), shared about the role of patients in the development of the Alopecia Areata Investigator Global Assessment (AA-IGA™), a five-grade scale to measure clinically meaningful treatment response to alopecia areata treatment for patients with 50 percent or more scalp hair loss. When reviewed with patients and clinicians, the AA-IGA™ was supported as a meaningful clinician-reported measure of scalp hair loss. The AA-IGA™ is available for others to use, with the goal of consistent measurement across alopecia areata research endeavors.
Future Research Priorities

- Define the relationship between hair regrowth and satisfaction with response, and determine the threshold for meaningful response for scalp hair regrowth.
- Determine how patients want to be engaged in their health care and treatment decisions and the characteristics of meaningful shared decisions.
- Develop a training tool for the use of the Severity on Alopecia Tool (SALT) that is available for clinical investigation and practice.
- Develop a Core Outcome Set suitable across clinical trials in alopecia areata that represent both patients’ and physicians’ priorities. This will:
  - Achieve agreement on what and how to measure (e.g., eyebrow and eyelash regrowth) and how best to use photos;
  - Define a core set of domains (outcomes) to be measured with input from all stakeholders; and
  - Identify or develop measurements that are sufficiently validated and sufficiently assess these domains.

PATIENT ENGAGEMENT IN CLINICAL DEVELOPMENT

Presentation Highlights

Patient Perspective
Dustin Lee shared his perspectives on alopecia areata as a patient, a researcher in the immunology field, and a NAAF Health and Research Ambassador (HARA). HARA ambassadors are a collaborative group of patients possessing not only the knowledge and first-hand experience of living with alopecia areata, but also having expertise in a variety of subjects that intersect nicely with the pharmaceutical industry to result in valuable insights. Lee described the value of HARA engagement in meaningful dialogue with industry to provide actionable feedback in a highly effective and impactful way in order to help direct treatment efforts toward the most desired end results for the patient community.

Industry Perspective
A panel of representatives from seven pharmaceutical companies (Aclaris Therapeutics, Bioniz Therapeutics, Concert Pharmaceuticals, Eli Lilly & Company, Legacy Healthcare, LEO Pharma and Pfizer) was convened to discuss their programs for alopecia areata, how patient participation is useful and where it is most needed.

All participants were passionate about their commitment to continuing patient engagement at every level to create greater efficiencies and better outcomes. A common theme of the discussion was centered on challenges posed by the U.S. health care system and ensuring all patients have access to treatments once they are approved. Real-world evidence is needed to create data-driven insights into patient lifestyles, preferences and decision-making processes in order to demonstrate the clinical and economic benefits of treatments so they are covered. The group agreed that collaboration is key to collecting, collating, and analyzing the right data to meet the needs of all stakeholders and help improve the lives of alopecia areata patients.

Future Research Priorities

- Evaluate the decision-making process a patient goes through when considering benefit versus risk of treatment options, including clinical trials.
- Determine how patients weigh effectiveness against side effects and inconvenience when deciding whether to continue, change or stop treatment.
- Predict which patients are likely to respond to which treatments.
- Address psychosocial and emotional impacts using terminology that does not increase stigma and acknowledges severity of the disease.
populations and lead to new therapeutic targets. These recent advances in identifying the molecular targets of immune response in alopecia areata are the result of many years of basic immunology research now coming to fruition, moving us closer to the immunologists’ dream of identifying and targeting the antigens and T-cell receptor clones that combine to drive the disease.

Dr. Aziz Ghahary, from the University of British Columbia (Vancouver, Canada), discussed his study to evaluate the inflammatory role of stage-specific embryonic antigen (SSEA) expressing cells in alopecia areata. This study revealed a novel approach to generate alopecia areata in C3H/HeJ mice by dermal injection of splenocyte-derived SSEA expressing cells, underscoring their potential role in driving inflammatory cascade and hair loss mechanisms.

Dr. Lynn Petukhova, from Columbia University (New York, NY), developed a novel analytic pipeline to identify mutations that contribute to alopecia areata etiology. Exome studies of rare variants in patients and family members indicate 12 genes from five genomic regions contribute to the hair follicle extracellular matrix, suggesting a crucial point of communication between the hair follicle and the immune system. Additional research could lead to the identification of a new biological point of intervention for inhibiting aberrant immune-mediated destruction of the hair follicle.

Future Research Priorities

- Microbiome studies to identify mechanisms of microbiome-associated induction and development of alopecia areata.
- Examination of immune-mediated mechanisms—and the roles of regulatory T cells, natural killer cells, gamma delta T cells, B cells, dendritic cells, chemokines, autoimmune regulators, monocytes and mast cells—for early intervention, prevention and restoration of immune privilege.
• Genetic architecture studies to identify biomarkers, molecular subtypes, and new therapeutically targetable pathways.
• Epigenetic studies of environmental factors that interact with gene expression.
• Identification of T cell receptor antigens/epitopes driving the disease.
• Investigations of the mechanisms of hair follicle biology, hair cycling and pigmentation in alopecia areata.

Presentation Highlights
Yamuna Rajoo, from RMIT University (Melbourne, Australia), presented a cross-sectional study to examine the associations between physical activity (PA), mental health and quality of life in 148 patients with alopecia areata. The majority of participants surveyed (91 or 61.5%) did not meet minimal physical activity levels according to Australia’s 2014 PA and Sedentary Behavior Guidelines. Results indicate that increasing physical activity levels in patients with alopecia areata may reduce symptoms of depression, anxiety and stress and improve mental well-being.

Dr. Amit Garg, from the Donald and Barbara Zucker School of Medicine (New Hyde Park, NY), shared examples from big data analyses in hidradenitis suppurativa to highlight the application of big data in making important observations on disease burden, disease course, co-morbid associations, disease outcomes, and treatment outcomes. Big data has the potential to harness both power and granularity to advance knowledge of alopecia areata.

Dr. Arash Mostaghimi, from Brigham & Women’s Hospital (Boston, MA), presented a cross-sectional study of 45,016 patients to establish the current point prevalence of alopecia areata among the general population in the United States. Participants screening positive for alopecia areata using the Alopecia Assessment Tool (ALTO) completed the Severity of Alopecia Tool (SALT) to determine severity and those with self-reported alopecia areata were invited to upload photographs for adjudication by three clinicians. Self-reported alopecia areata point prevalence was 1.14 percent overall, 1.24 percent among adults and 0.24 percent among adolescents. Based on photographs from 104 adults, clinician-adjudicated prevalence was 0.21 percent overall.

Dr. Jean-Phillip Okhovat, from Massachusetts General Hospital and Harvard Medical School (Boston, MA), presented a study of patients with alopecia areata focused on their willingness to pay (WTP) out of pocket (in US $) for a cure or control of their condition. Forty patients recruited from the dermatology clinic of UCLA completed the Alopecia Areata Symptom Impact Scale (AASIS) and a WTP questionnaire and were assessed by a dermatologist to calculate their SALT score. Results indicate that 33 percent of patients with alopecia areata were willing to pay ≥ $5,000 for a permanent cure and their median WTP as a percentage of monthly income was 10 to 20 percent—a figure that is comparable to that of atopic dermatitis and psoriasis patients.

Dr. Amy McMichael, from Wake Forest Baptist Medical Center (Winston Salem, NC), discussed ways to recruit, engage, educate, and study those of diverse backgrounds in alopecia areata trials. Strengthening ties to the community of affected patients at individual sites through increased cultural competency and commitment can overcome other barriers that potential study participants may consider. Identifying and prioritizing our research gaps for underrepresented groups in alopecia areata will help redefine a successful approach to more diverse studies.

Continued on page 6
Future Research Priorities

- Study the cumulative life-course impacts of alopecia areata and associated comorbidities on patients’ lives over time.
- Determine factors that influence differences in value to patients within populations, including differences in perspectives and priorities between patients, caregivers and physicians.
- Address the under-representation of real-world patient subsets in clinical studies.
- Identify practice gaps between a patient’s and a provider’s views of what is important and what works for patients.

Concluding Remarks

This two-day summit created new connections, increased dialogue and galvanized a diverse group of stakeholders to work together to advance research for alopecia areata patients and their families. The meeting underscored the rapid progress that has occurred since 2016, with Janus kinase (JAK) inhibitors being used widely with impressive effect, numerous biopharmaceutical companies pursuing new generations of systemic and topical treatments for alopecia areata, and expanding partnerships aimed at directing treatment efforts toward the most desired patient-centered outcomes.

Alopecia areata research summits are part of NAAF’s main strategic initiative, the Alopecia Areata Treatment Development Program (TDP). Many of the research accomplishments highlighted above have been part of the TDP, with NAAF either providing direct funding or acting as a concierge, leveraging our available research resources and clinical partnerships. The strategic goal of NAAF is to hasten discovery, approval of and access to safe, effective, affordable, easy-to-use treatments beneficial to the millions of people with alopecia areata. This summit celebrated another milestone on the focused path toward achieving that goal. Many of the Research Priorities proposed and discussed are projects that are in progress. NAAF has and will continue to provide support and leadership toward accomplishing these Future Research Priorities to help bring effective therapies for alopecia areata to market and enhance our understanding of this disease. We look forward to future discoveries.

Please contact us if you can help in any way or are interested in applying for funding to study any of the Future Research Priorities outlined in this article.